title: Oncolytic adenovirus retargeted to Delta-EGFR induces selective antiglioma activity.
abstract: The fact that glioblastomas, which are one of the most devastating cancers, frequently express the Delta-EGFR (epithelial growth factor receptor) also called mutant variant III of EGFR (EGFRvIII) suggests that this cancer cell-specific receptor might serve as an ideal target for cancer therapy. To assess its potential as such a target, we constructed an oncolytic adenovirus with Retargeted Infectivity Via EGFR (Delta-24-RIVER) on the backbone of Delta-24. This new oncolytic adenovirus targets, as Delta-24 does, the disrupted Rb pathway in cancer cells; in addition, this adenovirus has also been retargeted through the abrogation of CAR binding (Y477A mutation in adenoviral fiber protein) and insertion of an EGFRvIII-specific binding peptide in the HI loop of the fiber protein. As compared with Delta-24, Delta-24-RIVER induced EGFRvIII-selective cytotoxicity in U-87 MG isogenic cell lines and in tetracycline-inducible EGFRVIII expressing U-251 MG cells. Accordingly, by tittering the viral progeny and examining fiber protein expression in the above cells, we showed that the replication of this new construct also correlated with EGFRvIII expression. Consistently, immunohistochemistry staining of the adenoviral capsid protein hexon in the virus-treated tumors revealed that the virus replicated more efficiently in EGFRvIII-expressing U-87 MG.DeltaEGFR xenografts than in the tumors grown from U-87 MG cells. Importantly, treatment with Delta-24-RIVER prolonged the survival of animals with intracranial xenografts derived from U-87 MG.DeltaEGFR cells. Therefore, our results constitute the first proof of the direct targeting of a cancer-specific receptor using an oncolytic adenovirus.
authors.affiliation: Department of Neuro-Oncology, Brain Tumor Center, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
authors.forename: Y
authors.initials: Y
authors.lastname: Piao
authors.forename: H
authors.initials: H
authors.lastname: Jiang
authors.forename: R
authors.initials: R
authors.lastname: Alemany
authors.forename: V
authors.initials: V
authors.lastname: Krasnykh
authors.forename: F C
authors.initials: FC
authors.lastname: Marini
authors.forename: J
authors.initials: J
authors.lastname: Xu
authors.forename: M M
authors.initials: MM
authors.lastname: Alonso
authors.forename: C A
authors.initials: CA
authors.lastname: Conrad
authors.forename: K D
authors.initials: KD
authors.lastname: Aldape
authors.forename: C
authors.initials: C
authors.lastname: Gomez-Manzano
authors.forename: J
authors.initials: J
authors.lastname: Fueyo
mesh_terms: D000260:Adenoviruses, Human / Q000235:genetics / Q000502:physiology*; D000595:Amino Acid Sequence; D000818:Animals; D001932:Brain Neoplasms / Q000473:pathology / Q000628:therapy*; D045744:Cell Line, Tumor / Q000637:transplantation; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D005091:Exons / Q000235:genetics; D016161:Genes, Retinoblastoma; D018773:Genes, erbB-1; D005822:Genetic Vectors / Q000627:therapeutic use*; D005909:Glioblastoma / Q000473:pathology / Q000628:therapy*; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D008969:Molecular Sequence Data; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors* / Q000235:genetics; D050130:Oncolytic Virotherapy; D010446:Peptide Fragments / Q000235:genetics / Q000378:metabolism; D017384:Sequence Deletion; D014779:Virus Replication
chemical_list: D009363:Neoplasm Proteins; D010446:Peptide Fragments; C512478:EGFR protein, human; D066246:ErbB Receptors